{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:40:04Z","timestamp":1767922804126,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Mass Spectrom"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lurasidone is an antipsychotic drug clinically used for the treatment of schizophrenia and bipolar disorder. During a mechanism\u2010based forced degradation study of lurasidone, two novel degradation products were observed under free radical\u2010mediated oxidative (via AIBN) and solution photolytic conditions. The structures of the two novel degradants were identified through an approach combining HPLC, LC\u2010MS<jats:sup><jats:italic>n<\/jats:italic><\/jats:sup> (<jats:italic>n<\/jats:italic>\u00a0=\u20091, 2), preparative HPLC purification and NMR spectroscopy. The degradant formed under the free radical\u2010mediated condition is an oxidative degradant with half of the piperazine ring cleaved to form two formamides; a mechanism is proposed for the formation of the novel <jats:italic>N<\/jats:italic>,<jats:italic>N<\/jats:italic>\u2032\u2010diformyl degradant, which should be readily applicable to other drugs that contain a piperazine moiety that is widely present in drug molecules. The degradant observed under the solution photolytic condition is identified as the photo\u2010induced isomer of lurasidone with the benzisothiazole ring altered into a benzothiazole ring.<\/jats:p>","DOI":"10.1002\/jms.4871","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T10:53:46Z","timestamp":1654167226000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical\u2010mediated oxidative and photolytic conditions via liquid chromatography\u2010photodiode array\/ultraviolet\u2010tandem mass spectrometry and one\u2010dimensional\/two\u2010dimensional nuclear magnetic resonance spectroscopy"],"prefix":"10.1002","volume":"57","author":[{"given":"Kathy Cheng","family":"Wang","sequence":"first","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaohong","family":"Guo","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Kuang","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyang","family":"Jin","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenquan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"},{"name":"Quality Research Department of API Zhejiang Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8690-3451","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Excellence for Modern Analytical Technologies (CEMAT) Huahai Pharmaceutical Co., Ltd.  Linhai Zhejiang China"},{"name":"Huahai US, Inc.  Somerset New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"e_1_2_9_4_1","unstructured":"ICH Harmonised Tripartite Guideline Q1A (R2).Stability Testing of New Drug Substances and Products. Dated 6 February 2003."},{"key":"e_1_2_9_5_1","unstructured":"ICH Harmonised Tripartite Guideline Q1B.Stability testing: photostability testing of new drug substances and products. Dated 6 November 1996."},{"key":"e_1_2_9_6_1","first-page":"73","article-title":"Scientific considerations of forced degradation studies in ANDA submissions","volume":"36","author":"Maheswaran R","year":"2012","journal-title":"Pharm Tech"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.11.035"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2005.03.064"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.021"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4276"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21477"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.05.041"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2009.05.074"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.04.004"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.02.059"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.01.045"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.11.052"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","unstructured":"TianY ZhangH ZhuZ et al.A variation of Favorskii rearrangement mechanism under weakly acidic conditions: the case of clobetasol propionate degradation in solution. doi:10.26434\/chemrxiv.11809077.v1","DOI":"10.26434\/chemrxiv.11809077.v1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010020\u201002863\u20103"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9062"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","DOI":"10.1039\/9781849735360","volume-title":"Organic Chemistry of Drug Degradation. Chapter 3, Oxidative Degradation","author":"Li M","year":"2012"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8RA09152H"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2008.03.104"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.egypro.2013.05.116"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01571a068"},{"key":"e_1_2_9_26_1","first-page":"20","article-title":"Analysis of impurities and degradations in pharmaceuticals by high resolution tandem mass spectrometry and on\u2010line H\/D exchange LC\/MS","volume":"13","author":"Chen G","year":"2010","journal-title":"Am Pharm Rev"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040\u20104039(03)00028\u20105"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00706\u2010008\u20100038\u2010x"}],"container-title":["Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jms.4871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jms.4871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jms.4871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T17:51:27Z","timestamp":1760637087000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jms.4871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/jms.4871"],"URL":"https:\/\/doi.org\/10.1002\/jms.4871","archive":["Portico"],"relation":{},"ISSN":["1076-5174","1096-9888"],"issn-type":[{"value":"1076-5174","type":"print"},{"value":"1096-9888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"2022-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e4871"}}